Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with ...

Abrysvo has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older, as well as individuals aged 18 to 59 years at increased ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

RSV is a contagious virus causing severe respiratory infections in infants. Vaccination during pregnancy, provides newborns ...

Pregnant women across Australia will be offered a free vaccine to protect their babies against respiratory syncytial virus ...

Expectant mothers will have access to free vaccines against respiratory syncytial virus (RSV) from next month under a major ...

There are two immunizations recommended for infants, a maternal RSV vaccine (Pfizer's Abrysvo) given during pregnancy or an RSV antibody given to infants after birth. Is there a treatment for RSV?

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...